HealthTech: Insights into an Emerging Industry

Valuable Exits Reinforce Growing Investments

October 2019
# Table of Contents

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Industry Overview</td>
<td>3</td>
</tr>
<tr>
<td>HealthTech Investments</td>
<td>4</td>
</tr>
<tr>
<td>HealthTech Exits</td>
<td>29</td>
</tr>
<tr>
<td>Glossary</td>
<td>34</td>
</tr>
<tr>
<td>About the Authors</td>
<td>35</td>
</tr>
</tbody>
</table>
Valuable Exits Reinforce Growing Investments

Since 2015, the HealthTech industry has become one of the fastest-growing segments within healthcare. In fact, an SVB analysis finds that the number of private, venture-backed HealthTech financings has grown by 25% over that period, with SVB working with roughly 40% of combined US and European companies.

In this inaugural report, we introduce primary sectors and respective subsectors to measure their investment and exit activity. These sectors were derived by analyzing the problems around wasteful healthcare spending and then grouping companies based on their tech-enabled solutions to solve these problems.

Six primary sectors (see page 9 for full definitions):

- Provider Operations
- Alternative Care
- Clinical Trial Enablement
- Healthcare Navigation
- Medication Management
- Wellness & Education

Overall, the outlook for HealthTech is promising. In the past five years, the industry’s robust growth has facilitated more than $27B in invested capital for private companies and 14 companies with $1B+ valuations. Additionally, 2019 has already surpassed 2018 with a record $8B in total exit value, largely driven by strong IPOs.

HealthTech Team
Life Science & Healthcare
Silicon Valley Bank

Notes: Financing data includes private financings by venture-backed companies that have raised >$2M in US and Europe between 2015 and 09/13/19. Valuations mentioned here are defined as post-money valuations from PitchBook. Dates of financing rounds subject to change based on add-on investments. Source: PitchBook, SVB proprietary data and SVB analysis.
HealthTech Investments: Growth Across the Board
In 2019, Investment Is Up, Deal Count Is Down

Within the last five years, HealthTech deals have grown reliably year-over-year; however, for the first time ever, 2019 is predicted to come in lower than previous years due to a decrease in the number of deals in 2H 2019. Despite this decline, the total amount of dollars invested is up — indicating that companies are, on average, raising larger rounds.

VC Deals and Dollars (US & Europe)

In 2019, Investment Is Up, Deal Count Is Down

Within the last five years, HealthTech deals have grown reliably year-over-year; however, for the first time ever, 2019 is predicted to come in lower than previous years due to a decrease in the number of deals in 2H 2019. Despite this decline, the total amount of dollars invested is up — indicating that companies are, on average, raising larger rounds.

VC Deals and Dollars (US & Europe)

In 2019, Investment Is Up, Deal Count Is Down

Within the last five years, HealthTech deals have grown reliably year-over-year; however, for the first time ever, 2019 is predicted to come in lower than previous years due to a decrease in the number of deals in 2H 2019. Despite this decline, the total amount of dollars invested is up — indicating that companies are, on average, raising larger rounds.

VC Deals and Dollars (US & Europe)
US Leads World, UK Leads Europe in Investments

Countries with high healthcare expenditures also lead in total HealthTech funding. While healthcare costs are country specific, often the solutions targeting these costs are funded through cross-border participation. For example, in the last five years, 40% of all US deals have been syndicated with at least one European investor.

Countries with $200M+ VC Investment & Top Deals: 2015–2019
Total to Date: $27B+

- United States: $24B
- United Kingdom: $275M
- France: $599M
- Sweden: $202M
- Germany: $275M

Notes: Financing data includes private financings by venture-backed companies that have raised >$2M in US and Europe. Dates of financing rounds subject to change based on add-on investments. 2019 numbers through 09/13/19.
Source: PitchBook, SVB proprietary data and SVB analysis.
Rocky Mountain $ Projected to Double in 2019

While the West and Northeast remain at the top in terms of invested capital, the Rocky Mountains have become the nation’s fastest-growing region from 2018 to 2019. This recent surge can be attributed to an increase in the number of sizable deals within Colorado and Utah.

Growth in Key US Regions: 2017–2019

Notable Deals

Notes: Financing data includes private financings by venture-backed companies that have raised >$2M in US and Europe. Dates of financing rounds subject to change based on add-on investments. 2019 numbers through 09/13/19. Source: PitchBook, SVB proprietary data and SVB analysis.
Corporates Add Strategic Value at Multiple Stages

In the healthcare industry, startups commonly partner with incumbent players to gain traction. As these companies continue to innovate across the healthcare system, we expect to see a range of corporates — from biopharma and insurance to hospital systems — continue to make investments.

Most Active New Investors* in HealthTech: 2015–2019

**Corporate investor leads ≥ 50% of their total new investments. Source: PitchBook, SVB proprietary data and SVB analysis.
Wasteful Spending Drives Well-Funded Sectors
Total Funding & US Healthcare Waste for SVB’s Primary Sectors, 2015–2019

**Provider Operations**
Wastes $404B & $8.8B Invested
Increases the efficiency and accuracy of provider-provider, provider-patient interactions.

**Alternative Care**
Wastes $269B & $8.2B Invested
Provides primary or specialty care outside of a hospital or private practice.

**Clinical Trial Enablement**
Wastes $26B & $2.5B Invested
Solutions to accelerate drug discovery and the digitization of clinical trials.

**Healthcare Navigation**
Wastes $13B & $2.1B Invested
Guides users to relevant providers and/or payers based on their needs.

**Medication Management**
Wastes $24B & $1.4B Invested
Aids users in access and adherence to their prescribed medicine.

**Wellness & Education**
Wastes $26B & $1.3B Invested
Informs users of healthy lifestyle and medical best practices.

Notes: Financing data include private financings by venture-backed companies that have raised >$2M in US and Europe. Dates of financing rounds subject to change based on add-on investments. 2019 numbers through 09/13/19. Healthcare waste calculations are only for the US healthcare system; additional details are stated in the Glossary at the end of this report. Source: PitchBook, news articles, academic publications, Centers for Medicare & Medicaid Services, SVB proprietary data and SVB analysis.
Growth Is Projected to Continue

US-based Provider Operations companies have raised $1B+ each year for the last five years and 2019 is expected to set a record for deal and dollar volume. NorCal currently leads the nation, with 28% of all Provider Operations deals.

VC Deals and Dollars

Invested Capital by Round Size

Notes: Financing data include private financings by venture-backed companies that have raised >$2M in US and Europe. Dates of financing rounds subject to change based on add-on investments. 2019 numbers through 09/13/19.
Source: PitchBook, SVB proprietary data and SVB analysis.
**Workflow Optimization Raises $1B+ Again**

In the past three years, we have observed six mega rounds of $100M+. The four within Workflow Optimization alone raised $700M, or roughly 20% of the $3.7B total invested capital between 2017 and 2019 whereas the two in Clinical Decision Support raised $440M, accounting for nearly 25% of the $1.8B total invested capital during that period.

### All Provider Operations Deals by Subsector

<table>
<thead>
<tr>
<th>Subsector</th>
<th>2017</th>
<th>2018</th>
<th>2019</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Workflow Optimization</strong></td>
<td>$1.2B</td>
<td>$1.4B</td>
<td>$1.1B</td>
</tr>
<tr>
<td><strong>Clinical Decision Support</strong></td>
<td>$321M</td>
<td>$816M</td>
<td>$655M</td>
</tr>
</tbody>
</table>

### 2019 Deals > $100M

- **'TEMPUS**
- **HealthCatalyst**
- **PathAI**
- **ZnanyLekarz**
- **HeartFlow**

### 2019 Deals $50M–$100M

- **BostonGene**
- **REDOX**
- **innovaccer**
- **CoreCloud**
- **Commure**
- **BrightInsight**
- **healthverity**
- **CareSyntax**

### 2019 YTD Deals $25M–$50M

- **Congenica**
- **PicnicHealth**
- **artemis HEALTH**
- **Stratasan**

---

**Notes:** Financing data include private financings by venture-backed companies that have raised >$2M in US and Europe. Dates of financing rounds subject to change based on add-on investments. 2019 numbers through 09/13/19. Source: PitchBook, SVB proprietary data and SVB analysis.
Provider Operations

Hospital Operators Remain Committed

In addition to increasing operational efficiency, Provider Operations-focused companies have helped hospitals transition to a value-based care system. Investments within this sector by hospitals, such as Inova, or VC funds that have hospital LPs, such as Heritage Group, suggest that we may see additional integrated delivery networks supporting these startups.

Top Follow-on Investors

Follows-on in over 80% of financings

Follows-on in 75%-80% of financings

Follows-on in 60%-75% of financings

Round Size & Valuation Ranges

Series A

Series B

Notes: The follow-on percentile calculated as total follow-on investments/total investments within SVB’s HealthTech universe. Investor had a minimum of 3 total investments. *Mean calculated after excluding outliers that fell outside +/-1.5*IQR. Financing data includes private financings by venture-backed companies that have raised $2M in US and Europe from 2017 to 2019. Dates of financing rounds subject to change based on add-on investments. 2019 numbers through 09/13/19. Sample size for boxplots: Series A 75+ companies, Series B 50+ companies. Source: PitchBook, SVB proprietary data and SVB analysis.
Alternative Care
$ Projected to Outpace Other Sectors by $1B+

The rise in invested capital and increase in ≥$50M rounds can be attributed to companies needing more capital to validate the efficacy of their treatment within a clinical setting. From 2015 to the end of 2019, deals are projected to double and dollars to quintuple, with NorCal seeing the largest percentage of Alternative Care deals.

VC Deals and Dollars

Invested Capital by Round Size

Notes: Financing data include private financings by venture-backed companies that have raised >$2M in US and Europe. Dates of financing rounds subject to change based on add-on investments. 2019 numbers through 09/13/19.
Source: PitchBook, SVB proprietary data and SVB analysis.
$1B+ Raised in Primary Care & Mental Health

Invested capital within primary care has continued to far exceed that of specialty care. In fact, within the last two years, five specific deals have raised 45% of the total primary care capital. Similarly, mental health has doubled its invested capital since 2018, largely due to Click Therapeutics’ $305M corporate investment by Japan-based Otsuka Pharmaceutical.

Top* Alternative Care Deals by Subsector

<table>
<thead>
<tr>
<th>Subsector</th>
<th>2017 Invested Capital</th>
<th>2018 Invested Capital</th>
<th>2019 Invested Capital</th>
</tr>
</thead>
<tbody>
<tr>
<td>Primary Care</td>
<td>$574M</td>
<td>$1.6B</td>
<td>$1.4B</td>
</tr>
<tr>
<td>Mental Health</td>
<td>$175M</td>
<td>$311M</td>
<td>$640M</td>
</tr>
<tr>
<td>Women’s Health</td>
<td>$114M</td>
<td>$85M</td>
<td>$160M</td>
</tr>
<tr>
<td>Diabetes</td>
<td>$176M</td>
<td>$189M</td>
<td>$148M</td>
</tr>
<tr>
<td>Behavioral Health</td>
<td>$12M</td>
<td>$38M</td>
<td>$97M</td>
</tr>
<tr>
<td>Neurology</td>
<td>$45M</td>
<td>$100M</td>
<td></td>
</tr>
</tbody>
</table>

Notes: *Only showing top six subsectors by total invested capital within Alternative Care. Financing data include private financings by venture-backed companies that have raised >$2M in US and Europe. Dates of financing rounds subject to change based on add-on investments. 2019 numbers through 09/13/19. Source: PitchBook, SVB proprietary data and SVB analysis.
**Alternative Care**

**MH & Diabetes Land Most Valuable Deals**

Startups developing **clinically validated**, software-based solutions to prevent, manage, or treat healthcare conditions have begun to receive FDA approval. These digital therapeutics are becoming increasingly valuable, with one successful exit already on the books.

**Companies with a $50M+ Post-Money Valuation: 2017–2019**

### Diabetes

- **Livongo**
  - 4/11/18
  - $105M Round
  - $805M Post

- **omada**
  - 6/26/19
  - $73M Round
  - $593M Post

- **virta**
  - 4/4/18
  - $45M Round
  - $320M Post

- **lark**
  - 6/3/19
  - $46M Round
  - $241M Post

- **glooko**
  - 6/27/17
  - $35M Round
  - $140M Post

- **Glytec**
  - 6/7/17
  - $4M Round
  - $105M Post

- **metronom health**
  - 1/3/19
  - $7M Round
  - $65M Post

- **sano**
  - 1/12/18
  - $14M Round
  - $55M Post

### Mental Health (MH)

- **PEAR Therapeutics**
  - 1/4/19
  - $64M Round
  - $494 Post

- **Quartet**
  - 5/8/19
  - $60M Round
  - $490M Post

- **talkspace**
  - 5/29/19
  - $50M Round
  - $310M Post

- **AKILI**
  - 8/8/18
  - $68M Round
  - $258M Post

- **Lyra**
  - 12/17/18
  - $61M Round
  - $241M Post

- **mindstrong**
  - 12/21/18
  - $45M Round
  - $200M Post

### Nephrology

- **SOMATUS**
  - 3/20/18
  - $11M Round
  - $61M Post

- **Cricket Health**
  - 8/21/18
  - $24M Round
  - $50M Post

### Behavioral Health

- **noom**
  - 5/6/19
  - $58M Round
  - $340M Post

- **neurotrack**
  - 6/11/19
  - $21M Round
  - $110M Post

- **clock therapeutics**
  - 10/1/18
  - $17M Round
  - $82M Post

- **happify**
  - 8/15/17
  - $9M Round
  - $72M Post

### Women’s Health

- **NURX**
  - 7/11/19
  - $52M Round
  - $287M Post

- **MAVEN**
  - 9/26/18
  - $27M Round
  - $87M Post

### Cardiology

- **infoBionic**
  - 9/11/18
  - $50M Round
  - $63M Post

### Musculoskeletal

- **Hinge Health**
  - 8/9/18
  - $26M Round
  - $90M Post

### Ophthalmology

- **SimpleContacts**
  - 5/17/18
  - $16M Round
  - $76M Post

**Green box:** Company subsequently went public. **Purple text** indicates company has received FDA approval.

Notes: Post-money values reported by PitchBook for US and Europe venture-backed private companies. Dates of financing rounds subject to change based on add-on investments. 2019 financing through 09/13/19.

Source: PitchBook, Digital Therapeutics Alliance, SVB proprietary data and SVB analysis.
Alternative Care
Funded by a Cross-Sector Group of Big Players

As Alternative Care companies continue to provide opportunities for large employers to reduce their employees’ total healthcare expenditures, we will continue to see a range of corporates take interest. Cross-sector investors stand to benefit not only from a successful exit, but also from an employee productivity level.

Top Follow-on Investors

Funded by a Cross-Sector Group of Big Players

Notes: The follow-on percentile calculated as total follow-on investments/total investments within SVB’s HealthTech universe. Investor had a minimum of 3 total investments. *Mean calculated after excluding outliers that fell outside +/-1.5*IQR. Financing data include private financings by venture-backed companies that have raised >$2M in US and Europe from 2017 to 2019. Dates of financing rounds subject to change based on add-on investments. 2019 numbers through 09/13/19. Sample size for boxplots: Series A 50+ companies, Series B 35+ companies. Source: PitchBook, SVB proprietary data and SVB analysis.
Clinical Trial Enablement

Dollars Are Up, Deals Are Down

Strong inflows of capital remain within the Clinical Trial Enablement (CTE) sector, and 2019 is poised to double 2018 and reach $1B. However, total deals within the sector are predicted to decrease relative to 2018. Within the US, NorCal encompasses one-third of all CTE deals, followed by New York and Massachusetts, each with roughly 15%.

VC Deals and Dollars

- US
- Europe

2019 Estimate

Total Deals

<table>
<thead>
<tr>
<th>Year</th>
<th>Total Deals</th>
<th>US</th>
<th>Europe</th>
<th>≥$50M</th>
<th>$25M–$50M</th>
<th>$10M–$25M</th>
<th>$5M–$10M</th>
<th>≤$5M</th>
</tr>
</thead>
<tbody>
<tr>
<td>2015</td>
<td>19</td>
<td>144M</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>22M</td>
</tr>
<tr>
<td>2016</td>
<td>23</td>
<td>551M</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2017</td>
<td>30</td>
<td>497M</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2018</td>
<td>33</td>
<td>388M</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2019</td>
<td>31</td>
<td>71M</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Invested Capital by Round Size

- ≥$50M
- $25M–$50M
- $10M–$25M
- $5M–$10M
- ≤$5M

<table>
<thead>
<tr>
<th>Year</th>
<th>≥$50M</th>
<th>$25M–$50M</th>
<th>$10M–$25M</th>
<th>$5M–$10M</th>
<th>≤$5M</th>
</tr>
</thead>
<tbody>
<tr>
<td>2015</td>
<td>14%</td>
<td>7%</td>
<td>9%</td>
<td>8%</td>
<td>3%</td>
</tr>
<tr>
<td>2016</td>
<td>5%</td>
<td>4%</td>
<td>8%</td>
<td>6%</td>
<td>13%</td>
</tr>
<tr>
<td>2017</td>
<td>11%</td>
<td>18%</td>
<td>13%</td>
<td>14%</td>
<td>22%</td>
</tr>
<tr>
<td>2018</td>
<td>41%</td>
<td>27%</td>
<td>18%</td>
<td>20%</td>
<td>22%</td>
</tr>
<tr>
<td>2019</td>
<td>60%</td>
<td>57%</td>
<td>50%</td>
<td>56%</td>
<td>60%</td>
</tr>
</tbody>
</table>

Notes: Financing data include private financings by venture-backed companies that have raised >$2M in US and Europe. Dates of financing rounds subject to change based on add-on investments. 2019 numbers through 09/13/19.
Source: PitchBook, SVB proprietary data and SVB analysis.
Clinical Trial Enablement

$100M+ Mega Deals Return in 2019

The Drug Discovery Platform subsector remains at the forefront of the CTE field in terms of invested capital, predominantly due to its 2019 mega deal. The last mega deals were in 2017, one of which was PatientsLikeMe, a patient network and recruitment company that recently made headlines for being acquired by United Health Group after losing its foreign investors.

All Clinical Trial Enablement Deals by Subsector

<table>
<thead>
<tr>
<th>Subsector</th>
<th>2017</th>
<th>2018</th>
<th>2019</th>
</tr>
</thead>
<tbody>
<tr>
<td>Drug Discovery Platform</td>
<td>$116M</td>
<td>$162M</td>
<td>$247M</td>
</tr>
<tr>
<td>Workflow Optimization</td>
<td>$132M</td>
<td>$18M</td>
<td>$63M</td>
</tr>
<tr>
<td>Patient Recruitment</td>
<td>$203M</td>
<td>$61M</td>
<td>$68M</td>
</tr>
<tr>
<td>Genomic Analysis</td>
<td>$10</td>
<td>$10</td>
<td>$9</td>
</tr>
<tr>
<td>Mobile Trials</td>
<td>$39M</td>
<td>$35M</td>
<td>$35M</td>
</tr>
</tbody>
</table>

Notes: Financing data include private financings by venture-backed companies that have raised >$2M in US and Europe. Dates of financing rounds subject to change based on add-on investments. 2019 numbers through 09/13/19. Source: PitchBook, news articles, SVB proprietary data and SVB analysis.
Big Tech & Healthcare Investors Repeat

As companies increasingly turn to artificial intelligence/machine learning (AI/ML) to improve drug design and establish end-to-end solutions for clinical trial programs, they will continue to see interest from both tech and healthcare investors.

Top Follow-on Investors

Follows-on in **over 60%** of financings
- Founders Fund
- B Capital Group
- Balderton Capital
- Shumway Capital
- Foresight

Follows-on in **40%-60%** of financings
- Alphabet
- Andreessen Horowitz
- Sanofi

Follows-on in **25%-40%** of financings
- BlueCross BlueShield
- Village Ventures
- Plug and Play

Round Size & Valuation Ranges

**Series A**
- Round Size: $7M - $2M
- Pre-Money Valuation: $2M - $9M

**Series B**
- Round Size: $13M - $20M
- Pre-Money Valuation: $12M - $22M

**Series B**
- Pre-Money Valuation: $20M - $62M

Notes: The follow-on percentile calculated as total follow-on investments/total investments within SVB’s HealthTech universe. Investor had a minimum of 3 total investments. *Mean calculated after excluding outliers that fell outside +/-1.5*IQR. Financing data include private financings by venture-backed companies that have raised >$2M in US and Europe from 2017 to 2019. Dates of financing rounds subject to change based on add-on investments. 2019 numbers through 09/13/19. Sample size: Series A 15+ companies, Series B 7+ companies. Source: PitchBook, SVB proprietary data and SVB analysis.
New York & NorCal Lead Deals

New York ties NorCal with about 25% of all deals for Healthcare Navigation companies. Investments across the US have been strong, with larger rounds raised in the last two years and 2019 projected to have $1B+ total invested. While Europe has doubled its investments this year, the growth is driven by large deals from Doctolib (France) and ZnanyLekarz (Poland).

VC Deals and Dollars

Invested Capital by Round Size

Notes: Financing data include private financings by venture-backed companies that have raised >$2M in US and Europe. Dates of financing rounds subject to change based on add-on investments. 2019 numbers through 09/13/19.
Source: PitchBook, SVB proprietary data and SVB analysis.
Startups that focus on helping consumers find the right provider and/or health plan have dominated invested capital. Of the three $100M+ mega rounds, Collective Health (Payer Matching) raised two, and Doctolib (Provider Matching) raised the other. Doctolib and Grand Rounds (Provider Matching) now lead the sector with $700M+ valuations.

All Healthcare Navigation Deals by Subsector

<table>
<thead>
<tr>
<th>Subsector</th>
<th>2017</th>
<th>2018</th>
<th>2019</th>
</tr>
</thead>
<tbody>
<tr>
<td>Provider Matching</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2019 Deals over $50M</td>
<td>$166M</td>
<td>$225M</td>
<td>$477M</td>
</tr>
<tr>
<td>2019 Deals $25M–$50M</td>
<td>19</td>
<td>12</td>
<td>17</td>
</tr>
<tr>
<td>2019 Deals $10M–$25M</td>
<td>$83M</td>
<td>$242M</td>
<td>$205M</td>
</tr>
<tr>
<td>2019 Deals $10M–$25M</td>
<td>7</td>
<td>8</td>
<td>2</td>
</tr>
<tr>
<td>Price Transparency</td>
<td>$16M</td>
<td>$20M</td>
<td>$38M</td>
</tr>
<tr>
<td>2019 Deals $10M–$25M</td>
<td>4</td>
<td>2</td>
<td>3</td>
</tr>
</tbody>
</table>

Notes: Financing data include private financings by venture-backed companies that have raised >$2M in US and Europe. Dates of financing rounds subject to change based on add-on investments. 2019 numbers through 09/13/19.
Source: PitchBook, SVB proprietary data and SVB analysis.
Payers have started to venture into the HealthTech industry. Strategic interest from corporates aligns with companies that aid patients in choosing in-network plans and/or ensuring they are referred to the proper physician.

### Top Follow-on Investors

Follows-on in **over 80%** of financings

- Accel
- Y Combinator
- NEA
- bpifrance

Follows-on in **50%–80%** of financings

- OPTUM
- PJC
- SJF Ventures
- Fidelity
- Maverick Ventures

Follows-on in **30%–50%** of financings

- Adams Street Partners
- Aflac
- BlueCross BlueShield
- Plug and Play

### Round Size & Valuation Ranges

#### Series A

- **75th Percentile**
- **Mean** (*)
- **Median**

<table>
<thead>
<tr>
<th>Round Size</th>
<th>Pre-Money Valuation</th>
</tr>
</thead>
<tbody>
<tr>
<td>$6M</td>
<td>$11M</td>
</tr>
<tr>
<td>$7M</td>
<td>$19M</td>
</tr>
<tr>
<td>$2M</td>
<td>$9M</td>
</tr>
</tbody>
</table>

#### Series B

- **75th Percentile**
- **Mean** (*)
- **Median**

<table>
<thead>
<tr>
<th>Round Size</th>
<th>Pre-Money Valuation</th>
</tr>
</thead>
<tbody>
<tr>
<td>$51M</td>
<td>$19M</td>
</tr>
<tr>
<td>$59M</td>
<td>$17M</td>
</tr>
<tr>
<td>$55M</td>
<td>$5M</td>
</tr>
</tbody>
</table>

### Notes:

- The follow-on percentile calculated as total follow-on investments/total investments within SVB’s HealthTech universe. Investor had a minimum of 3 total investments. *Mean calculated after excluding outliers that fell outside +/-1.5*IQR. Financing data include private financings by venture-backed companies that have raised >$2M in US and Europe from 2017 to 2019. Dates of financing rounds subject to change based on add-on investments. 2019 numbers through 09/13/19. Sample size: Series A 15+ companies, Series B 8+ companies. Source: PitchBook, SVB proprietary data and SVB analysis.
In the past five years, US companies collectively raised $1B+ of capital and have led the Medication Management sector in Europe. This growth can be attributed to the larger deals in 2018 and 2019. Additionally, in the US, NorCal encompasses 40% of total deals, and New York follows at 20%.

### VC Deals and Dollars

<table>
<thead>
<tr>
<th>Year</th>
<th>US</th>
</tr>
</thead>
<tbody>
<tr>
<td>2015</td>
<td>$9M</td>
</tr>
<tr>
<td>2016</td>
<td>$8M</td>
</tr>
<tr>
<td>2017</td>
<td>$9M</td>
</tr>
<tr>
<td>2018</td>
<td>$4M</td>
</tr>
<tr>
<td>2019</td>
<td>$14M</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Year</th>
<th>Europe</th>
</tr>
</thead>
<tbody>
<tr>
<td>2015</td>
<td>$137M</td>
</tr>
<tr>
<td>2016</td>
<td>$254M</td>
</tr>
<tr>
<td>2017</td>
<td>$295M</td>
</tr>
<tr>
<td>2018</td>
<td>$248M</td>
</tr>
<tr>
<td>2019</td>
<td>$409M</td>
</tr>
</tbody>
</table>

### Invested Capital by Round Size

- **≥$50M**: 8%, 25%, 33%, 34%, 2%
- **$25M–$50M**: 8%, 7%, 12%, 52%, 59%
- **$10M–$25M**: 11%, 20%, 46%, 8%, 2%
- **$5M–$10M**: 6%, 22%, 13%, 30%, 60%
- **≤$5M**: 2%, 25%, 13%, 59%, 59%

Notes: Financing data include private financings by venture-backed companies that have raised >$2M in US and Europe. Dates of financing rounds subject to change based on add-on investments. 2019 numbers through 09/13/19. Source: PitchBook, SVB proprietary data and SVB analysis.
Medication Management

Delivery Leads with Capsule’s Record Deal

Consumer-facing solutions that ensure users have access to and are compliant with their prescriptions are responsible for 77% of total investments, thanks largely in part to Capsule Pharmacy’s $200M deal in 2019. This space has already seen one strong exit with PillPack’s (Medication Delivery) acquisition by Amazon in 2018.

All Medication Management Deals by Subsector

<table>
<thead>
<tr>
<th>Subsector</th>
<th>2017</th>
<th>2018</th>
<th>2019</th>
</tr>
</thead>
<tbody>
<tr>
<td>Medication Compliance</td>
<td>$65M</td>
<td>$58M</td>
<td>$54M</td>
</tr>
<tr>
<td>Medication Delivery</td>
<td>$89M</td>
<td>$174M</td>
<td>$314M</td>
</tr>
<tr>
<td>Workflow Optimization</td>
<td>$32M</td>
<td>$5M</td>
<td>$43M</td>
</tr>
<tr>
<td>Pharmacy Benefits</td>
<td>$118M</td>
<td>$15M</td>
<td>$12M</td>
</tr>
</tbody>
</table>

Notes: Financing data include private financings by venture-backed companies that have raised >$2M in US and Europe. Dates of financing rounds subject to change based on add-on investments. 2019 numbers through 09/13/19. Source: PitchBook, SVB proprietary data and SVB analysis.
Biopharma corporate involvement in Medication Management, as well as from distribution and logistics companies, signifies interest in improving patients’ access to their medications.

**Top Follow-on Investors**

- **Follows-on in over 60% of financings**
  - Blumberg Capital
  - Founders Fund
  - Hikma
  - McKesson
  - Thrive Capital
  - NextGen Venture Partners

- **Follows-on in 30%–60% of financings**
  - Box Group

- **Follows-on in 20%–30% of financings**
  - Social Capital

**Round Size & Valuation Ranges**

**Series A**

- 75th Percentile: $51M
- Mean*: $25M
- Median: $19M
- Top Follow-on Investors: Blumberg Capital, Founders Fund, Hikma, McKesson, Thrive Capital, NextGen Venture Partners
- Round Size: $9M, $12M, $20M
- Pre-Money Valuation: $7M, $9M, $19M

**Series B**

- 75th Percentile: $57M
- Mean*: $43M
- Median: $24M
- Round Size: $13M
- Pre-Money Valuation: $25M, $34M

**Notes:** The follow-on percentile calculated as total follow-on investments/total investments within SVB’s HealthTech universe. Investor had a minimum of 3 total investments. *Mean calculated after excluding outliers that fell outside +/-1.5*IQR. Financing data include private financings by venture-backed companies that have raised >$2M in US and Europe from 2017 to 2019. Dates of financing rounds subject to change based on add-on investments. 2019 numbers through 09/13/19. Sample size: Series A 14+ companies, Series B 7+ companies. Source: PitchBook, SVB proprietary data and SVB analysis.
Wellness & Education Deals Triple Since 2015

US investment into Wellness & Education companies has doubled, driven by $≥50M deals. Notably, NorCal dominated the space, with 30% of Wellness & Education deals falling within the region; New York, Massachusetts, SoCal and Washington came in next with 6% of total deals within the sector.

VC Deals and Dollars

Invested Capital by Round Size

Notes: Financing data include private financings by venture-backed companies that have raised $>2M in US and Europe. Dates of financing rounds subject to change based on add-on investments. 2019 numbers through 09/13/19. Source: PitchBook, SVB proprietary data and SVB analysis.
Marquee Deal Lands Calm $1B+ Valuation

This year marked the first time that a Health & Wellness company has raised a $100M+ financing. The deal resulted in Calm becoming valued at a $1B+ post-money valuation. In contrast, Medical Education’s growth in 2019 isn’t due to a single mega round, but from multiple financings in line with previous years’ deal sizes.

All Wellness & Education Deals by Subsector

<table>
<thead>
<tr>
<th></th>
<th>2017</th>
<th>2018</th>
<th>2019</th>
</tr>
</thead>
<tbody>
<tr>
<td>Health &amp; Wellness</td>
<td>$74M</td>
<td>$142M</td>
<td>$322M</td>
</tr>
<tr>
<td>Medical Education</td>
<td>$82M</td>
<td>$57M</td>
<td>$139M</td>
</tr>
</tbody>
</table>

2019 Deals over $100M

2019 Deals $50M–$100M

2019 Deals $10M–$50M

Notes: Financing data include private financings by venture-backed companies that have raised >$2M in US and Europe. Dates of financing rounds subject to change based on add-on investments. 2019 numbers through 09/13/19. Source: PitchBook, SVB proprietary data and SVB analysis.
D2C investor backing within Wellness & Education has driven the highest pre-money Series B valuation across all HealthTech sectors. In fact, Wellness & Education’s mean Series B has nearly tripled that of the next highest sector, Healthcare Navigation.

**Top Follow-on Investors**

- **Follows-on in over 80% of financings**
  - HealthInvest Equity Partners
  - Canaan

- **Follows-on in 50%-80% of financings**
  - Illumina
  - Andreessen Horowitz
  - Forerunner Ventures

- **Follows-on in 30%-50% of financings**
  - Felix Ventures
  - Philips
  - Felix Capital
  - Balderton Capital

**Round Size & Valuation Ranges**

<table>
<thead>
<tr>
<th>Series A</th>
<th>Series B</th>
</tr>
</thead>
<tbody>
<tr>
<td>Round Size</td>
<td>Pre-Money Valuation</td>
</tr>
<tr>
<td>75th Percentile</td>
<td>Mean*</td>
</tr>
<tr>
<td>50th Percentile</td>
<td>Median</td>
</tr>
</tbody>
</table>

Notes: The follow-on percentile calculated as total follow-on investments / total investments within SVB’s HealthTech universe. Investor had a minimum of 3 total investments. *Mean calculated after excluding outliers that fell outside +/-1.5*IQR. Financing data include private financings by venture-backed companies that have raised >$2M in US and Europe from 2017 to 2019. Dates of financing rounds subject to change based on add-on investments. 2019 numbers through 09/13/19. Sample size: Series A 18+ companies, Series B 10+ companies. Source: PitchBook, SVB proprietary data and SVB analysis.
HealthTech Exits:
2019 Ends IPO Drought
Highly Valued 2019 IPOs Dominate Exits

Through September 2019, the market cap of 2019 IPOs accounts for nearly 90% of total exit value, despite there being only five IPOs and 28 M&A deals. This year we saw Livongo go public — the first Alternative Care company to do so — subsequently validating the idea that entrepreneurs can build these types of companies and achieve an ROI for their investors.

<table>
<thead>
<tr>
<th>HealthTech Companies with $750M+ Market Cap*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Company</td>
</tr>
<tr>
<td>---------</td>
</tr>
<tr>
<td>Inovalon</td>
</tr>
<tr>
<td>Livongo</td>
</tr>
<tr>
<td>Change Healthcare</td>
</tr>
<tr>
<td>Health Catalyst</td>
</tr>
<tr>
<td>Tabularasa Healthcare</td>
</tr>
<tr>
<td>Phreesia</td>
</tr>
</tbody>
</table>

Notes: M&A defined as private, venture-backed M&A deals and LBOs, and IPO defined as private, venture-backed IPO. Company’s primary HQ is US and Europe based on Pitchbook. The market cap at IPO is used to estimate the value of public companies. M&A deal value is equal to the total acquisition price for the company, only reporting publicly disclosed deal values. *Current market cap as of 9/30/2019. 2019 numbers through 09/30/19. Source: PitchBook, news articles, CapIQ, SVB proprietary data and SVB analysis.
Provider Operations Lead M&A Activity

While Provider Operations has consistently led the number of M&A deals within the HealthTech industry, each sector has seen at least one successful M&A deal. The median age for a company is about 5 years after its first financing, with Clinical Trial Enablement companies taking 4–5+ years longer, most likely due to lengthy clinical trial processes.

Number of M&A Deals by SVB Sectors

<table>
<thead>
<tr>
<th>Sector</th>
<th>2015</th>
<th>2016</th>
<th>2017</th>
<th>2018</th>
<th>2019</th>
</tr>
</thead>
<tbody>
<tr>
<td>Healthcare Navigation</td>
<td>1</td>
<td>10</td>
<td>15</td>
<td>21</td>
<td>14</td>
</tr>
<tr>
<td>Wellness &amp; Education</td>
<td>4</td>
<td>4</td>
<td>2</td>
<td>3</td>
<td>5</td>
</tr>
<tr>
<td>Medication Management</td>
<td>5</td>
<td>2</td>
<td>6</td>
<td>4</td>
<td>1</td>
</tr>
<tr>
<td>Clinical Trial Enablement</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alternative Care</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Provider Operations</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Top Acquisitions by Deal Value in Each Sector

1. **Bracket**
   - HQ: Wayne, PA
   - Asthma & COPD management company
   - Acquired in January 2019 at a $225M valuation

2. **ResMed**
   - HQ: San Diego, CA
   - Device company focusing on breathing disorders
   - Acquired in January 2019 at a $225M valuation

3. **Hill-Rom**
   - HQ: Chicago, IL
   - Provider of hospital equip. & medical supplies
   - Acquired in May 2019 at a $195M valuation

4. **Biotelemetry**
   - HQ: Malvern, PA
   - Provider of monitoring & pop. health services
   - Acquired in March 2019 at a $65M valuation

5. **Propeller**
   - HQ: Madison, WI
   - Asthma & COPD management company
   - Acquired in September 2018 at a $1.0B valuation

6. **C-R-F Health**
   - HQ: England, UK
   - Electronic clinical outcome assessment company
   - Acquired in September 2018 at a $1.0B valuation

7. **Voalte**
   - HQ: Sarasota, FL
   - Hospital point-of-care communication platform
   - Acquired in March 2019 at a $65M valuation

Notes: M&A defined as private, venture-backed M&A and LBOs of companies in US and Europe. 2019 numbers through 09/30/19.
Source: PitchBook, SVB proprietary data and SVB analysis.
Tech Companies Active in HealthTech M&A

Last year, a noteworthy 25% of HealthTech startups were acquired by a tech company, and nearly 30% of M&A deals between 2015 and 2019 had at least one corporate investor. Interestingly, when a healthcare corporate investor was part of a company’s investment syndicate, the company was 80% more likely to be acquired by a healthcare company.

Number of M&A Deals by Acquirer Type

- Healthcare
- Technology

Notable Acquisitions by Healthcare & Tech Acquirers

Acquired by a Healthcare company:
- flatiron: 2/1/18, $1.9B Deal Value, Acquirer: Roche
- practice fusion: 2/13/18, $100M Deal Value, Acquirer: Allscripts
- REDBRICK HEALTH: 5/21/18, $156M Deal Value, Acquirer: Virgin Pulse
- Propeller: 1/7/19, $225M Deal Value, Acquirer: ResMed
- Volaris: 5/8/19, $195M Deal Value, Acquirer: Hill-Rom Holdings

Acquired by a Technology company:
- PillPack: 6/28/18, $1.0B Deal Value, Acquirer: Amazon
- BOLDER Healthcare Solutions: 3/12/18, $485M Deal Value, Acquirer: Cognizant
- invicro: 9/25/17, $285M Deal Value, Acquirer: Konica Minolta
- SCIO health analytics: 5/1/18, $240M Deal Value, Acquirer: EXL Service
- twine health: 2/14/18, $17M Deal Value, Acquirer: Fitbit

Notes: M&A defined as private, venture-backed M&A and LBOs of companies in US and Europe. Healthcare acquirer defined as a company with primary business within the Healthcare industry; Technology acquirer defined as a company with primary business within the Technology sector. *Company was always PE-backed, not VC-backed. 2019 numbers through 09/30/19. Source: PitchBook, SVB proprietary data and SVB analysis.
California Leads Rest of Nation in M&A Deals

While California continues to lead in M&A deals, Massachusetts is the only state that has seen consistent exit growth since 2015. Regionally, the Northeast has dominated M&A deals, with 51% of its exits coming from the Provider Operations sector. Additionally, the Northeast is also a hotbed for Clinical Trial Enablement (CTE) acquisitions, comprising roughly 70% of all CTE exits.

Top States with M&A Deals: 2015–2019

Notable Exits

- **California**: MediTouch, mytrus, HealthDecision
- **Massachusetts**: Herald, SHYFT, Smart Scheduling
- **New York**: flatiron, GENEVA, SMARTANALYST
- **Texas**: DIGITAL PHARMACIST, CancerGeneConnect
- **Minnesota**: ABILITY, provation, Redbrick Health
- **Washington**: PREVISER, SPIRAL GENETICS, C-SATS, TALYST

Notes: M&A defined as private, venture-backed M&A deals and LBOs. 2019 numbers through 09/30/19. Northeast defined as ME, NH, VT, NY, MA, NJ, CT, and PA. Source: PitchBook, SVB proprietary data and SVB analysis.
Glossary

Alternative Care Definitions

Primary Care defined as solutions for preventive health measures by a provider or licensed care coach.

Neurology defined as solutions for pain, Alzheimer’s disease, motor functions, autism, motion sickness, fall prevention and select sleep disorders.

Mental Health defined as providing solutions and coaching to treat psychiatric issues.

Behavioral Health defined as targeting lifestyle habits that lead to substance abuse, addiction and obesity.

Women’s Health defined as reproductive monitoring and primary care for women.

Musculoskeletal defined as muscular and mobility disorders.

Cardiology defined as hypertension, cardiac arrhythmia and chronic heart failure.

Nephrology defined as treatment of kidney-related diseases.

Diabetes defined as treatment of insulin resistance or lack thereof.

Ophthalmology defined as eye-related and eyesight disorders.

Deal Descriptions

Total Deal Value defined as the full value of the acquisition, including any milestones to be earned.

Types of Investors

Corporate Investor defined as both corporate venture and parent company investment into venture-backed companies.

Follow-on Investor defined as an investor making an investment in the subsequent round of the same company.

Statistical Measures

Interquartile Range (IQR) defined as the difference between the 75th percentile and 25th percentile.

Subsector Definitions

Workflow Optimization defined as the automation and/or integration of a provider’s day-to-day processes.

Clinical Decision Support defined as solutions that help a provider make the right decision at the right time.

Genomic Analysis defined as end-to-end bioinformatics data analytics.

Drug Discovery Platform defined as data-driven drug discovery.

Mobile Trials defined as decentralized clinical trials.

Health & Wellness defined as solutions that encourage a healthier lifestyle; users do not directly interact with a provider.

Medication Compliance defined as solutions for medication adherence and tracking.

Pharmacy Benefits defined as solutions to increase access to prescription drugs and make them more affordable.

US Healthcare Wasteful Spending Definitions

Provider Operations defined as the combination of provider and administrative tasks that could be automated as well as the expense associated with the overutilization of diagnostic procedures.

Alternative Care defined as the expense from avoidable emergency room visits and hospital readmissions.

Clinical Trial Enablement defined as the expense from US-based, registered, results-posted clinical trials that experience delays.

Healthcare Navigation defined as the expense from patient referral leakage and clinically inappropriate referrals.

Wellness & Education defined as the expense due to a provider or patients’ lack of knowledge about medical best practices.

Medication Management defined as the expense due to lack of medication adherence for patients prescribed 3+ drugs.
About the Authors

**Chris Moniz**
Managing Director  
HealthTech & Device  
cmoniz@svb.com

Chris heads the Bay Area and Northwest HealthTech and Medical Device vertical for SVB’s Life Science & Healthcare Practice. Having been with SVB since 2006, Chris was previously a member of a Growth-Stage team focused on software companies and a member of the Corporate Finance group. He holds a bachelor’s in finance from Sonoma State University.

**Dhruv Vig, Ph.D.**
Sr. Associate  
HealthTech  
dvig@svb.com

Dhruv leverages a combination of SVB’s priority data, its vantage point within the innovation ecosystem and healthcare industry knowledge to build strategic relationships and publish thought-leadership pieces. Before joining SVB, Dhruv co-founded a HealthTech company and was part of the SRI (formerly Stanford Research Institute) Ventures team. He holds a Ph.D. from the University of Arizona and completed a postdoctoral fellowship at Johns Hopkins University in computational biophysics.

**Kevin Longo**
Managing Director  
HealthTech & Device  
klongo@svb.com

Kevin heads the Northeast HealthTech & Medical Device practice, geographically responsible for all activity in these sectors from New York City up through Eastern Canada. Over his 12 years at SVB, Kevin has worked with a wide variety of technology and life science companies, providing solutions to companies, from early and pre-VC to late-stage, high-growth international public companies. Kevin holds a bachelors from Hofstra University.

**Matt Griffiths**
Director  
HealthTech & Device  
mgriffiths@svb.com

Matt helps run the Northeast HealthTech & Medical Device practice, geographically responsible for all activity in these sectors from New York City up through Eastern Canada. Over his 9+ years at SVB, Matt has worked with companies ranging from biopharma and diagnostics to software and hardware. He has provided solutions to companies, from early and pre-VC companies to late-stage, high-growth international public companies. Matt holds a bachelors from The College of the Holy Cross in Worcester, Massachusetts.

**Brandon Clark**
Sr. Vice President  
HealthTech  
bclark@svb.com

Brandon helps spearhead HealthTech efforts, geographically working with companies in the San Francisco Bay Area, the Pacific Northwest and Western Canada. During his 8+ years at SVB, Brandon has worked with companies across HealthTech, synthetic biology, diagnostics, biopharma and software, ranging from brand-new startups to global public companies. Brandon holds a bachelor’s in economics and political science from San Diego State University.
Disclaimers

This material including, without limitation, to the statistical information herein, is provided for informational purposes only. The material is based in part on information from third-party sources that we believe to be reliable but which have not been independently verified by us, and for this reason, we do not represent that the information is accurate or complete. The information should not be viewed as tax, investment, legal or other advice, nor is it to be relied on in making an investment or other decision. You should obtain relevant and specific professional advice before making any investment decision. Nothing relating to the material should be construed as a solicitation, offer or recommendation to acquire or dispose of any investment or to engage in any other transaction.

Silicon Valley Bank is registered in England and Wales at Alphabeta, 14-18 Finsbury Square, London EC2A 1BR, UK under No. FCO29579. Silicon Valley Bank is authorised and regulated by the California Department of Business Oversight and the United States Federal Reserve Bank; authorised by the Prudential Regulation Authority with number 577295; and subject to regulation by the Financial Conduct Authority and limited regulation by the Prudential Regulation Authority. Details about the extent of our regulation by the Prudential Regulation Authority are available from us on request.

Silicon Valley Bank, a public corporation with limited liability (Aktiengesellschaft) under the laws of the U.S. federal state of California, with registered office in Santa Clara, California, U.S.A. is registered with the California Secretary of State under No. C1175907, Chief Executive Officer (Vorstand): Gregory W. Becker, Chairman of the Board of Directors (Aufsichtsratsvorsitzender): Roger F Dunbar.

Silicon Valley Bank Germany Branch is a branch of Silicon Valley Bank. Silicon Valley Bank Germany Branch with registered office in Frankfurt am Main is registered with the local court of Frankfurt am Main under No. HRB 112038, Branch Directors (Geschäftsführer): Oscar C. Jazdowski, John K. Peck. Competent Supervisory Authority: Bundesanstalt für Finanzdienstleistungsaufsicht (BaFin), Graurheindorfer Straße 108, 53117 Bonn, Germany.

Silicon Valley Bank, an authorized bank branch under the Bank Act (Canada).

©2019 SVB Financial Group. All rights reserved. SVB, SVB FINANCIAL GROUP, SILICON VALLEY BANK, MAKE NEXT HAPPEN NOW and the chevron device are trademarks of SVB Financial Group, used under license. Silicon Valley Bank is a member of the FDIC and the Federal Reserve System. Silicon Valley Bank is the California bank subsidiary of SVB Financial Group (Nasdaq: SIVB).
About Silicon Valley Bank
For more than 35 years, Silicon Valley Bank has helped innovative companies and their investors move bold ideas forward, fast. SVB provides targeted financial services and expertise through its offices in innovation centers around the world. With commercial, international and private banking services, SVB helps address the unique needs of innovators.

See complete disclaimers on previous page.
©2019 SVB Financial Group. All rights reserved. SVB, SVB FINANCIAL GROUP, SILICON VALLEY BANK, MAKE NEXT HAPPEN NOW and the chevron device are trademarks of SVB Financial Group, used under license. Silicon Valley Bank is a member of the FDIC and the Federal Reserve System. Silicon Valley Bank is the California bank subsidiary of SVB Financial Group (Nasdaq: SIVB).